GLP-1 Demand — Obesity Drug Supply/Demand Signal
Eli Lilly's GLP-1 agonists (Mounjaro for diabetes, Zepbound for obesity) represent the fastest product ramp in pharmaceutical history.
The obesity epidemic (42% of US adults obese) combined with GLP-1's unprecedented efficacy (20%+ body weight loss) creates demand exceeding any prior pharmaceutical launch by 5-10x.
Lilly's stock has been repriced as a pharmaceutical-plus-platform company with a $130B+ TAM.
The signal mechanism:
Supply constraints (manufacturing limitations) are the primary near-term variable — demand clearly exceeds supply at current pricing ($1,000+/month).
Each quarter that manufacturing capacity expansion lags demand, Lilly leaves revenue on the table and delays the revenue ramp.
Conversely, capacity announcements (new manufacturing sites, auto-injector supply deals) are immediate re-rating catalysts as analysts pull forward the revenue curve.
Want to act on this signal?
Explore broker options →Barfinex is not an investment advisor. This is not financial advice.
Barfinex may earn a commission if you open an account.